

Electronic Acknowledgement Receipt

EFS ID:	8487846
Application Number:	09589288
International Application Number:	
Confirmation Number:	1519
Title of Invention:	METHODS OF INHIBITING B LYMPHOCYTES USING ANTIBODIES TO NEUTROKINE-ALPHA
First Named Inventor/Applicant Name:	Guo-Liang Yu
Customer Number:	73326
Filer:	John Jr. Kilyk/Rebecca Dise
Filer Authorized By:	John Jr. Kilyk
Attorney Docket Number:	PF343P3C5
Receipt Date:	23-SEP-2010
Filing Date:	08-JUN-2000
Time Stamp:	18:45:47
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 940
RAM confirmation Number	7903
Deposit Account	121216
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	FinalRejectioninUS12210134_mailed07212010.pdf	1043224	no	21
			b388aee08361e8f37cef8db145d7f9899aec4ce8		
Warnings:					
Information:					
2	NPL Documents	El-Hallak-JPediatr-2007.pdf	550253	no	7
			1e72b4a610c43a88e870199d2c561cf9a663d31a		
Warnings:					
Information:					
3	NPL Documents	Tan-ArthritisRheum-1997.pdf	1024939	no	11
			7fa0967f3b60b39671e1d9eeb225fb69cc240a72		
Warnings:					
Information:					
4	NPL Documents	Petri-NEnglJMed-2005.pdf	897947	no	11
			72cccc53407e74248aaf46f9c822a6776b76f2b9		
Warnings:					
Information:					
5	NPL Documents	Sauge-Merle-EurJBiochem-1999.pdf	1036416	no	8
			fd50b42b695810a5ae41b6e4cf127871e395f1dd		
Warnings:					
Information:					
6	NPL Documents	Esposito-JImmunol-1999.pdf	1304787	no	6
			53ee53f32331a138d50d798e296da1279a7f31b0		
Warnings:					
Information:					
7	NPL Documents	InternationalSearchReport-PCT_US01-25850-2003.pdf	304461	no	7
			2018f3cd73ccf93d8d3a00fec1331bffb5a3b446		
Warnings:					
Information:					
8	NPL Documents	InternationalSearchReport-PCT_US01-25891-2003.pdf	284516	no	7
			e4877d710f2d8eb8fa5aa1c17fa615e0459950ba		
Warnings:					
Information:					

9	NPL Documents	RRin09932322_mailed06302004.pdf	282174	no	8
			9d29d3869c9906e44e42664057b4810d7c12b1ad		
Warnings:					
Information:					
10	NPL Documents	NonFinalRejectionin09932322_mailed02092005.pdf	361079	no	10
			803d78ad05857121ecd696c17ea05eabb855a560		
Warnings:					
Information:					
11	NPL Documents	FinalRejectionin09932322_mailed08242005.pdf	352168	no	8
			4353d3e0e7fa44d1eaafbe3b96e771fba53e75		
Warnings:					
Information:					
12	NPL Documents	NOAin09932322_mailed02082006.pdf	587623	no	11
			1e8c357bb5eb73a70b3724bca5b451678f06f7c6		
Warnings:					
Information:					
13	NPL Documents	Han-Virology-1998.pdf	1203721	no	11
			3add902b724a5fecdd13641753a719058e61a8bdf		
Warnings:					
Information:					
14	NPL Documents	NonFinalRejectionin12135025_mailed08042010.pdf	13181985	no	151
			04c4defe757c1f6433d8c181ded3ebdc042307f3		
Warnings:					
Information:					
15	NPL Documents	NOAinUS11054515_mailed09092010.PDF	934803	no	5
			796b8b786465368b121f3b4fc3fe863681bc9845		
Warnings:					
Information:					
16	NPL Documents	NonFinalRejectionin12605202_mailed09202010.PDF	2057360	no	64
			f98d933173590526ba618da1f60b0dbe9c1918a5		
Warnings:					
Information:					
17	NPL Documents	Berenbaum-ClinExplimmunol-1977.pdf	2097647	no	18
			a3f9e5ad8fe70bf72977d6ad975fddefeae0789c		
Warnings:					
Information:					

18	NPL Documents	Dooley-JAM Soc Nephrol-1999.pdf	548447	no	7
			46ff6c1b0eaf0fe94fb148f1b54441b014aed328		
Warnings:					
Information:					
19	NPL Documents	Jonsson-IntImmunopharmacol-2003.pdf	498768	no	7
			08761046fff2029905a623e19177f0b44c324d41		
Warnings:					
Information:					
20	NPL Documents	Koyama-AnnRheumDis-2005.pdf	396787	no	3
			36750cbf8cfddeb9af3265c197270dae37faaeb9		
Warnings:					
Information:					
21	NPL Documents	Ramanujam-JImmunol-2004.pdf	1400623	no	11
			c21109af80b33f965b4e1ae09f0215ab342aa830		
Warnings:					
Information:					
22	NPL Documents	Stohl-ClinImmunol-2002.pdf	747456	no	8
			56cca5a81e36ae45c7fd6b9425f3ef5bac934ae1		
Warnings:					
Information:					
23	NPL Documents	RRinUS12210134_mailed11302009.pdf	4728183	no	74
			cf65d3dea324ca393288e24ac634894615794411		
Warnings:					
Information:					
24	NPL Documents	1982RevisedCriteriaforClassificationofSLE.pdf	69670	no	2
			da9d4ae107d793ccd0fdd41c200f6d8e5ad396c2		
Warnings:					
Information:					
25	NPL Documents	ResponsetoAppealLetterLilly-EP_0939804-2009.pdf	118815	no	2
			94bdd42e0dfbe961b2cb16937be14f20a4b563f5		
Warnings:					
Information:					
26	NPL Documents	ResponsetoAppealLilly-EP_0939804-2009.pdf	3290843	no	50
			1a56e670f8d212d3bfd1e48f017a84ee8f4a23cc		
Warnings:					
Information:					

27	Petition to Withdraw from Issue	PetitionWithdrawFromIssue.pdf	40242 b0f71e5ecfd989012b9f923ef815b713b106e468	no	2
Warnings:					
Information:					
28	Request for Continued Examination (RCE)	RCETransmittal.pdf	80818 c4864bc8377d1148bd4ba640a736d3cb94fd8a24	no	2
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
29	Amendment Submitted/Entered with Filing of CPA/RCE	Amendment.pdf	510115 834f499a33b597a23f8fc18291c7e3846e4399dd	no	16
Warnings:					
Information:					
30	Transmittal Letter	IDS-13th.pdf	239608 53c1ca2d9e37f5aac371105f5b8c58730a1e5c36	no	5
Warnings:					
Information:					
31	Information Disclosure Statement (IDS) Filed (SB/08)	1449-13th.pdf	737420 f299f5c3306896b105f5b5ccd77220fa9066ac30	no	8
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
32	Fee Worksheet (PTO-875)	fee-info.pdf	32662 064472de3592d89f8b2d6ca97e178ac46684f3ed	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			40945560		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.